Background: In assessing the clinical response to medical and/or surgical treatments in patients with established Cushing’s syndrome, the need for an instrument that could measure the magnitude of changes in the most common symptoms was felt. We therefore tested the usefulness of a simple clinical index, the Cushing’s syndrome severity index (CSI), based on clinimetric principles. Eight clinical features were selected. Each one was graded on an ordinal 3-point scale (0–2) with specification of anchor points based on severity. The total score ranged from 0 to 16. Methods: Interrater agreement, construct validity and concurrent validity of the index were evaluated. Fourteen patients with Cushing’s syndrome were evaluated independently by 2 endocrinologists before and after successful treatment. The CSI and two global scales of illness severity were administered. Urinary cortisol measurements were also performed. Results: The intraclass correlation coefficient of the CSI was 0.95 before treatment and 0.87 after treatment. The CSI significantly discriminated (p < 0.001) the effects of treatment and paralleled the changes in urinary cortisol. There were significant correlations between CSI and global scales of illness severity and change after treatment. Conclusion: The results indicate that the CSI is a valid and reliable clinimetric method to evaluate severity in Cushing’s syndrome. It may provide a tool for better assessing the complex array of signs and symptoms in this condition. The index is suitable for descriptive studies, outcome investigations and treatment trials.

Keywords:
Cushing’s syndrome, Adrenal, Clinimetrics, Cortisol, Rating scales, Depression, Health outcome
1.
Engel GL: Clinical observation: The neglected basic method of medicine. JAMA 1965;192:849–852.
2.
Engel GL: How much longer must medicine’s science be bound by a seventeenth century world view? Psychother Psychosom 1992;57:3–16.
3.
Feinstein AR: Clinical judgement revisited. Ann Intern Med 1994;120:799–805.
4.
Danese RD, Aron DC: Principles of clinical epidemiology and their application to the diagnosis of Cushing’s syndrome. Endocrinologist 1994;4:339–346.
5.
Howlett TA, Rees LH, Besser GM: Cushing’s syndrome. Clin Endocrinol Metab 1985;14:911–945.
6.
Ross EJ, Linch DC: Cushing’s syndrome-killing disease: Discriminatory values of signs and symptoms aiding early diagnosis. Lancet 1982;ii:646–649.
7.
Urbanic RC, George JM: Cushing’s disease. Medicine 1981;60:14–24.
8.
Feinstein AR: An additional basic science for clinical medicine. IV. The development of clinimetrics. Ann Intern Med 1983;99:843–848.
9.
Feinstein AR: Clinimetrics. New Haven, Yale University Press, 1987.
10.
Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–1447.
11.
Burch HB, Wartofsky L: Graves’ ophthalmopathy: Current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747–793.
12.
Seshadri MS, Samuel BU, Kanagasabapathy AS, Cherian AM: Clinical scoring system for hypothyroidism. J Gen Intern Med 1989;4:490–492.
13.
Zulewsky H, Muller D, Exer P, Miserez AR, Staub JJ: Estimation of tissue hypothyroidism by a new clinical score: Evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 1997;82:771–776.
14.
Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M: Risk factors and long-term outcome in pituitary-dependent Cushing’s disease. J Clin Endocrinol Metab 1996;81:2647–2652.
15.
Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D: Ketoconazole treatment in Cushing’s syndrome: Experience in 34 patients. Clin Endocrinol (Oxf) 1991;35:347–352.
16.
Fleiss JL: The Design and Analysis of Clinical Experiments. New York, Wiley, 1986, p 1.
17.
Fleiss JL: Statistical Methods for Rates and Proportions. New York, Wiley, 1981, p 212.
18.
Kramer MS, Feinstein AR: The biostatistics of concordance. Clin Pharmacol Ther 1981;29:111–123.
19.
Kellner R: Improvement criteria in drug trials with neurotic patients. Part 2. Psychol Med 1972;2:73–80.
20.
Sonino N, Fava GA, Belluardo P, Girelli ME, Boscaro M: Course of depression in Cushing’s syndrome. Horm Res 1993;39:202–206.
21.
Fava GA: Screening and diagnosis of depression. Dis Manag Health Outcome 1997;2:1–7.
22.
Fava GA, Mangelli L: Subclinical symptoms of panic disorder: New insights into pathophysiology and treatment. Psychother Psychosom 1999;68:281–289.
23.
De Jong GM, van Sonderen E, Emmelkamp PMG: A comprehensive model of stress. Psychother Psychosom 1999;68:290–298.
24.
Sonino N, Fava GA: A simple instrument for assessing stress in clinical practice. Postgrad Med J 1998;74:408–410.
25.
Fava GA, Kellner R, Lisansky J, Park S, Perini GI, Zielezny M: Rating depression in normals and depressives. J Affect Disord 1986;11:29–33.
26.
Fava GA, Kellner R, Munari F, Pavan L: The Hamilton Depression Rating Scale in normals and depressives. Acta Psychiatr Scand 1982;66:26–32.
27.
Rafanelli C, Park SK, Ruini C, Ottolini F, Cazzaro M, Fava GA: Rating well-being and distress. Stress Med 2000;16:55–61.
28.
Sonino N, Fallo F, Boscaro M: Ketoconazole and other inhibitors of steroid production: Current use. Med Sci Res 1989;17:131–134.
29.
Fallo F, Sonino N, Barzon L, Pistorello M, Pagotto U, Paoletta A, Boscaro M: Effect of surgical treatment on hypertension in Cushing’s syndrome. Am J Hypertens 1996;9:77–80.
30.
Sonino N, Fava GA: Psychosomatic aspects of Cushing’s disease. Psychother Psychosom 1998;67:140–146.
31.
Engel GL: From biomedical to biopsychosocial: Being scientific in the human domain. Psychother Psychosom 1997;66:57–62.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.